VC: Investing preapproval too risky

An interview with med tech VC investor Dave Eichler of Psilos explores the current venture investing landscape in the sector. He said his firm is focused on growth capital for medical device companies and no longer seeks to invest preapproval. Psilos used to invest in early-stage med tech but doesn't any longer since the risk/reward calculation wasn't making sense. The firm also focuses on technology that can lower the cost and improve the quality of healthcare. Molecular breast imaging is of particular interest to Eichler currently. More

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.